• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Viatris to Report Second Quarter 2025 Financial Results on August 7, 2025

    6/12/25 4:30:00 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VTRS alert in real time by email

    PITTSBURGH, June 12, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) will report second quarter 2025 financial results on Thursday, August 7, 2025. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results.

    Viatris OUS Logo (PRNewsfoto/Viatris Inc.)

    Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website.

    About Viatris

    Viatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale, currently supplying high-quality medicines to approximately 1 billion patients around the world annually and touching all of life's moments, from birth to the end of life, acute conditions to chronic diseases. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access takes on deep meaning at Viatris. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on LinkedIn, Instagram, YouTube and X.

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/viatris-to-report-second-quarter-2025-financial-results-on-august-7-2025-302480469.html

    SOURCE Viatris Inc.

    Get the next $VTRS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VTRS

    DatePrice TargetRatingAnalyst
    6/6/2025$10.00Neutral
    Goldman
    7/19/2024$15.00Buy
    Jefferies
    10/23/2023$13.00 → $9.00Neutral → Underperform
    BofA Securities
    6/23/2023$11.00Equal Weight → Underweight
    Barclays
    4/24/2023$11.00Overweight → Equal Weight
    Barclays
    2/17/2023$16.00 → $14.00Outperform → Market Perform
    BMO Capital Markets
    1/27/2023$13.00 → $15.00Hold → Buy
    Jefferies
    11/10/2022$9.00 → $12.00Sell → Neutral
    UBS
    More analyst ratings

    $VTRS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Smith Scott Andrew bought $536,262 worth of shares (60,000 units at $8.94), increasing direct ownership by 26% to 292,807 units (SEC Form 4)

      4 - Viatris Inc (0001792044) (Issuer)

      5/14/25 6:00:11 PM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Korman Harry bought $61,252 worth of shares (4,403 units at $13.91), increasing direct ownership by 6% to 94,960 units (SEC Form 4)

      4 - Viatris Inc (0001792044) (Issuer)

      10/25/24 4:30:03 PM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTRS
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Viatris Inc.

      SCHEDULE 13G - Viatris Inc (0001792044) (Subject)

      5/14/25 10:45:26 AM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Viatris Inc.

      SCHEDULE 13G/A - Viatris Inc (0001792044) (Subject)

      5/8/25 10:20:37 AM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Viatris Inc.

      10-Q - Viatris Inc (0001792044) (Filer)

      5/8/25 9:21:14 AM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman initiated coverage on Viatris with a new price target

      Goldman initiated coverage of Viatris with a rating of Neutral and set a new price target of $10.00

      6/6/25 8:33:51 AM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies resumed coverage on Viatris with a new price target

      Jefferies resumed coverage of Viatris with a rating of Buy and set a new price target of $15.00

      7/19/24 8:34:32 AM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Viatris downgraded by BofA Securities with a new price target

      BofA Securities downgraded Viatris from Neutral to Underperform and set a new price target of $9.00 from $13.00 previously

      10/23/23 7:20:20 AM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care